NeuroSense Therapeutics Ltd. Proceeds from Debt, Net of Issuance Costs
NeuroSense Therapeutics Ltd. (NRSN) reported Proceeds from Debt, Net of Issuance Costs of $306.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-03-31
| Period end | Proceeds from Debt, Net of Issuance Costs | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|
| 2024-12-31 | $306.00K 20-F · filed 2026-03-31 | |
| 2023-12-31 | $439.00K 20-F · filed 2026-03-31 | |
| 2022-06-08 | $217.00K 6-K · filed 2024-06-17 | |
| 2021-12-09 | $681.00K 6-K · filed 2024-06-17 |